Susanne Jank1,2, Thilo Bertsche1,2, Dieter Schellberg3, Wolfgang Herzog3, Walter E Haefeli4. 1. Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, Medizinische Klinik (Krehl-Klinik), University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. 2. Cooperation Unit Clinical Pharmacy, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. 3. Department of Internal Medicine II, Psychosomatic and General Internal Medicine, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. 4. Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, Medizinische Klinik (Krehl-Klinik), University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. walter.emil.haefeli@med.uni-heidelberg.de.
Abstract
OBJECTIVE: To develop a questionnaire ("A14") for the description of adherence and individual barriers as basis for adherence-enhancing interventions in the clinical and pharmaceutical setting, and to compare it to the validated German MMAS (Morisky Medication Adherence Scale). METHOD: Fourteen questions with a 5-item likert-scale from "never" (4) to "very often" (0) were given to 150 medical inpatients. According to their score, patients were classified into non-adherent (score <50) or adherent (score 50-56). On the dichotomous MMAS, "yes" is scored 0 and "no" 1 point, a total score of 4 indicating adherence. Patients with complete scales were compared with the remaining patients regarding socio-demographic factors. Descriptive statistics, Cronbach's Alpha, Spearman correlation, and kappa were computed. RESULTS: Eighty-three participants completed both scales. Patients with missing values differed significantly regarding age, education, and adherence according to MMAS. Cronbach's Alpha for A14 was 0.861. MMAS and A14 median total scores were 4 and 52, respectively. About 39.5% of patients were non-adherent as per MMAS compared to 40% as per A14; kappa was 0.262 (P = 0.016). The total scores correlated with a Rho-value of 0.43 (P < 0.001). CONCLUSION: The A14-scale showed good internal consistency and a significant correlation with the MMAS suggesting that it merits further investigation.
OBJECTIVE: To develop a questionnaire ("A14") for the description of adherence and individual barriers as basis for adherence-enhancing interventions in the clinical and pharmaceutical setting, and to compare it to the validated German MMAS (Morisky Medication Adherence Scale). METHOD: Fourteen questions with a 5-item likert-scale from "never" (4) to "very often" (0) were given to 150 medical inpatients. According to their score, patients were classified into non-adherent (score <50) or adherent (score 50-56). On the dichotomous MMAS, "yes" is scored 0 and "no" 1 point, a total score of 4 indicating adherence. Patients with complete scales were compared with the remaining patients regarding socio-demographic factors. Descriptive statistics, Cronbach's Alpha, Spearman correlation, and kappa were computed. RESULTS: Eighty-three participants completed both scales. Patients with missing values differed significantly regarding age, education, and adherence according to MMAS. Cronbach's Alpha for A14 was 0.861. MMAS and A14 median total scores were 4 and 52, respectively. About 39.5% of patients were non-adherent as per MMAS compared to 40% as per A14; kappa was 0.262 (P = 0.016). The total scores correlated with a Rho-value of 0.43 (P < 0.001). CONCLUSION: The A14-scale showed good internal consistency and a significant correlation with the MMAS suggesting that it merits further investigation.
Authors: Jerry H Gurwitz; Terry S Field; Leslie R Harrold; Jeffrey Rothschild; Kristin Debellis; Andrew C Seger; Cynthia Cadoret; Leslie S Fish; Lawrence Garber; Michael Kelleher; David W Bates Journal: JAMA Date: 2003-03-05 Impact factor: 56.272
Authors: Elisabeth Höld; Johanna Grüblbauer; Martin Wiesholzer; Daniela Wewerka-Kreimel; Stefan Stieger; Werner Kuschei; Philip Kisser; Elisabeth Gützer; Ursula Hemetek; Astrid Ebner-Zarl; Jürgen Pripfl Journal: Trials Date: 2022-04-14 Impact factor: 2.728
Authors: Alexander Mertens; Christopher Brandl; Talya Miron-Shatz; Christopher Schlick; Till Neumann; Andreas Kribben; Sven Meister; Clarissa Jonas Diamantidis; Urs-Vito Albrecht; Peter Horn; Stefan Becker Journal: Medicine (Baltimore) Date: 2016-09 Impact factor: 1.889
Authors: Jingjing Pan; Lian Wu; Huichuan Wang; Tao Lei; Bin Hu; Xiaorong Xue; Qiongge Li Journal: Medicine (Baltimore) Date: 2019-07 Impact factor: 1.817
Authors: Christiane Muth; Sebastian Harder; Lorenz Uhlmann; Justine Rochon; Birgit Fullerton; Corina Güthlin; Antje Erler; Martin Beyer; Marjan van den Akker; Rafael Perera; André Knottnerus; Jose M Valderas; Ferdinand M Gerlach; Walter E Haefeli Journal: BMJ Open Date: 2016-07-25 Impact factor: 2.692